Zacks.com on MSN19h
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in EuropeThe EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...
AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with ...
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...
Archer-Daniels-Midland Co. restated previous earnings, after earlier this month identifying new accounting errors, in a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback